nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—STAT5B—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00501	0.0227	CbGpPWpGaD
Dasatinib—STAT5B—IL2 signaling events mediated by STAT5—IL2—vaginal cancer	0.00463	0.021	CbGpPWpGaD
Dasatinib—MAP3K3—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00445	0.0202	CbGpPWpGaD
Dasatinib—HCK—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00397	0.018	CbGpPWpGaD
Dasatinib—CSK—uterine cervix—vaginal cancer	0.00378	0.00484	CbGeAlD
Dasatinib—SIK3—female reproductive system—vaginal cancer	0.00376	0.00482	CbGeAlD
Dasatinib—RIPK2—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00374	0.017	CbGpPWpGaD
Dasatinib—TESK1—endometrium—vaginal cancer	0.00373	0.00478	CbGeAlD
Dasatinib—STK36—urethra—vaginal cancer	0.00373	0.00478	CbGeAlD
Dasatinib—EPHB3—urethra—vaginal cancer	0.00373	0.00478	CbGeAlD
Dasatinib—HCK—uterine cervix—vaginal cancer	0.00373	0.00478	CbGeAlD
Dasatinib—BMPR1B—uterus—vaginal cancer	0.00373	0.00478	CbGeAlD
Dasatinib—STAT5B—IL-5 Signaling Pathway—IL2—vaginal cancer	0.00368	0.0167	CbGpPWpGaD
Dasatinib—STK36—endometrium—vaginal cancer	0.00367	0.00471	CbGeAlD
Dasatinib—EPHB3—endometrium—vaginal cancer	0.00367	0.00471	CbGeAlD
Dasatinib—TNK2—uterus—vaginal cancer	0.00365	0.00469	CbGeAlD
Dasatinib—TESK1—mammalian vulva—vaginal cancer	0.00361	0.00463	CbGeAlD
Dasatinib—STK36—mammalian vulva—vaginal cancer	0.00355	0.00455	CbGeAlD
Dasatinib—EPHB3—mammalian vulva—vaginal cancer	0.00355	0.00455	CbGeAlD
Dasatinib—LIMK2—endometrium—vaginal cancer	0.00355	0.00455	CbGeAlD
Dasatinib—STAT5B—IL-2 Signaling Pathway—IL2—vaginal cancer	0.00354	0.016	CbGpPWpGaD
Dasatinib—RIPK2—epithelium—vaginal cancer	0.00353	0.00454	CbGeAlD
Dasatinib—RIPK2—uterine cervix—vaginal cancer	0.0035	0.0045	CbGeAlD
Dasatinib—ZAK—female reproductive system—vaginal cancer	0.00349	0.00448	CbGeAlD
Dasatinib—CSK—urethra—vaginal cancer	0.00347	0.00445	CbGeAlD
Dasatinib—LIMK2—mammalian vulva—vaginal cancer	0.00343	0.0044	CbGeAlD
Dasatinib—HCK—urethra—vaginal cancer	0.00343	0.0044	CbGeAlD
Dasatinib—SIK1—uterine cervix—vaginal cancer	0.00342	0.00439	CbGeAlD
Dasatinib—SIK3—female gonad—vaginal cancer	0.00342	0.00439	CbGeAlD
Dasatinib—CSK—endometrium—vaginal cancer	0.00342	0.00438	CbGeAlD
Dasatinib—STAT5B—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00341	0.0154	CbGpPWpGaD
Dasatinib—ERBB3—epithelium—vaginal cancer	0.00338	0.00434	CbGeAlD
Dasatinib—EPHB3—uterus—vaginal cancer	0.00338	0.00434	CbGeAlD
Dasatinib—HCK—endometrium—vaginal cancer	0.00337	0.00433	CbGeAlD
Dasatinib—ERBB3—uterine cervix—vaginal cancer	0.00335	0.0043	CbGeAlD
Dasatinib—BMPR1B—female reproductive system—vaginal cancer	0.00335	0.0043	CbGeAlD
Dasatinib—MAP3K19—female reproductive system—vaginal cancer	0.00335	0.0043	CbGeAlD
Dasatinib—MAP3K2—uterine cervix—vaginal cancer	0.00332	0.00426	CbGeAlD
Dasatinib—CSK—mammalian vulva—vaginal cancer	0.0033	0.00424	CbGeAlD
Dasatinib—TNK2—female reproductive system—vaginal cancer	0.00328	0.00421	CbGeAlD
Dasatinib—LIMK2—uterus—vaginal cancer	0.00327	0.00419	CbGeAlD
Dasatinib—HCK—mammalian vulva—vaginal cancer	0.00326	0.00418	CbGeAlD
Dasatinib—STAT5B—Interleukin-2 signaling—IL2—vaginal cancer	0.00323	0.0146	CbGpPWpGaD
Dasatinib—RIPK2—urethra—vaginal cancer	0.00322	0.00413	CbGeAlD
Dasatinib—ZAK—female gonad—vaginal cancer	0.00318	0.00408	CbGeAlD
Dasatinib—BTK—IL-5 Signaling Pathway—IL2—vaginal cancer	0.00318	0.0144	CbGpPWpGaD
Dasatinib—RIPK2—endometrium—vaginal cancer	0.00317	0.00407	CbGeAlD
Dasatinib—SRMS—Immune System—EIF4A3—vaginal cancer	0.00317	0.0144	CbGpPWpGaD
Dasatinib—ZAK—vagina—vaginal cancer	0.00316	0.00405	CbGeAlD
Dasatinib—MAPK14—epithelium—vaginal cancer	0.00315	0.00404	CbGeAlD
Dasatinib—CSK—uterus—vaginal cancer	0.00315	0.00404	CbGeAlD
Dasatinib—SIK1—urethra—vaginal cancer	0.00314	0.00404	CbGeAlD
Dasatinib—MAPK14—uterine cervix—vaginal cancer	0.00312	0.00401	CbGeAlD
Dasatinib—EPHA4—urethra—vaginal cancer	0.00311	0.00399	CbGeAlD
Dasatinib—LCK—uterine cervix—vaginal cancer	0.00311	0.00399	CbGeAlD
Dasatinib—HCK—uterus—vaginal cancer	0.00311	0.00399	CbGeAlD
Dasatinib—SIK1—endometrium—vaginal cancer	0.0031	0.00397	CbGeAlD
Dasatinib—EPHA5—vagina—vaginal cancer	0.00309	0.00397	CbGeAlD
Dasatinib—TESK1—female reproductive system—vaginal cancer	0.00309	0.00396	CbGeAlD
Dasatinib—BMPR1B—female gonad—vaginal cancer	0.00305	0.00391	CbGeAlD
Dasatinib—EPHB3—female reproductive system—vaginal cancer	0.00304	0.0039	CbGeAlD
Dasatinib—STK36—female reproductive system—vaginal cancer	0.00304	0.0039	CbGeAlD
Dasatinib—BTK—female gonad—vaginal cancer	0.00303	0.00389	CbGeAlD
Dasatinib—JAK2—Interferon Signaling—EIF4A3—vaginal cancer	0.00303	0.0137	CbGpPWpGaD
Dasatinib—BTK—vagina—vaginal cancer	0.00301	0.00387	CbGeAlD
Dasatinib—SIK1—mammalian vulva—vaginal cancer	0.00299	0.00384	CbGeAlD
Dasatinib—TNK2—female gonad—vaginal cancer	0.00299	0.00383	CbGeAlD
Dasatinib—EPHB4—epithelium—vaginal cancer	0.00299	0.00383	CbGeAlD
Dasatinib—JAK2—epithelium—vaginal cancer	0.00297	0.0038	CbGeAlD
Dasatinib—EPHA4—mammalian vulva—vaginal cancer	0.00296	0.0038	CbGeAlD
Dasatinib—EPHB4—uterine cervix—vaginal cancer	0.00296	0.0038	CbGeAlD
Dasatinib—JAK2—uterine cervix—vaginal cancer	0.00294	0.00377	CbGeAlD
Dasatinib—LIMK2—female reproductive system—vaginal cancer	0.00294	0.00377	CbGeAlD
Dasatinib—EPHA2—epithelium—vaginal cancer	0.00293	0.00376	CbGeAlD
Dasatinib—EPHA2—uterine cervix—vaginal cancer	0.0029	0.00373	CbGeAlD
Dasatinib—FYN—uterine cervix—vaginal cancer	0.0029	0.00372	CbGeAlD
Dasatinib—YES1—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.0029	0.0131	CbGpPWpGaD
Dasatinib—STAT5B—IL2-mediated signaling events—IL2—vaginal cancer	0.00289	0.0131	CbGpPWpGaD
Dasatinib—FGR—urethra—vaginal cancer	0.00286	0.00367	CbGeAlD
Dasatinib—LCK—urethra—vaginal cancer	0.00286	0.00367	CbGeAlD
Dasatinib—SIK1—uterus—vaginal cancer	0.00285	0.00366	CbGeAlD
Dasatinib—STK35—female reproductive system—vaginal cancer	0.00285	0.00365	CbGeAlD
Dasatinib—BTK—Regulation of toll-like receptor signaling pathway—IFNA1—vaginal cancer	0.00284	0.0129	CbGpPWpGaD
Dasatinib—MAP4K5—uterine cervix—vaginal cancer	0.00283	0.00364	CbGeAlD
Dasatinib—MAP3K3—uterine cervix—vaginal cancer	0.00283	0.00364	CbGeAlD
Dasatinib—CSK—female reproductive system—vaginal cancer	0.00283	0.00363	CbGeAlD
Dasatinib—EPHA4—uterus—vaginal cancer	0.00282	0.00362	CbGeAlD
Dasatinib—FGR—endometrium—vaginal cancer	0.00281	0.00361	CbGeAlD
Dasatinib—TESK1—female gonad—vaginal cancer	0.00281	0.00361	CbGeAlD
Dasatinib—ERBB3—uterus—vaginal cancer	0.0028	0.00359	CbGeAlD
Dasatinib—TESK1—vagina—vaginal cancer	0.00279	0.00358	CbGeAlD
Dasatinib—MAP3K2—uterus—vaginal cancer	0.00277	0.00355	CbGeAlD
Dasatinib—STK36—female gonad—vaginal cancer	0.00277	0.00355	CbGeAlD
Dasatinib—EPHB3—female gonad—vaginal cancer	0.00277	0.00355	CbGeAlD
Dasatinib—EPHB3—vagina—vaginal cancer	0.00275	0.00353	CbGeAlD
Dasatinib—STK36—vagina—vaginal cancer	0.00275	0.00353	CbGeAlD
Dasatinib—FGR—mammalian vulva—vaginal cancer	0.00272	0.00349	CbGeAlD
Dasatinib—LCK—mammalian vulva—vaginal cancer	0.00272	0.00349	CbGeAlD
Dasatinib—EPHB4—urethra—vaginal cancer	0.00272	0.00349	CbGeAlD
Dasatinib—EPHB6—uterine cervix—vaginal cancer	0.00271	0.00347	CbGeAlD
Dasatinib—JAK2—urethra—vaginal cancer	0.0027	0.00347	CbGeAlD
Dasatinib—HCK—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.0027	0.0122	CbGpPWpGaD
Dasatinib—TXK—Immune System—EIF4A3—vaginal cancer	0.00269	0.0122	CbGpPWpGaD
Dasatinib—EPHB4—endometrium—vaginal cancer	0.00268	0.00344	CbGeAlD
Dasatinib—LIMK2—female gonad—vaginal cancer	0.00267	0.00343	CbGeAlD
Dasatinib—EPHA2—urethra—vaginal cancer	0.00267	0.00343	CbGeAlD
Dasatinib—FYN—urethra—vaginal cancer	0.00266	0.00342	CbGeAlD
Dasatinib—JAK2—endometrium—vaginal cancer	0.00266	0.00341	CbGeAlD
Dasatinib—LIMK2—vagina—vaginal cancer	0.00266	0.00341	CbGeAlD
Dasatinib—FMO3—mammalian vulva—vaginal cancer	0.00263	0.00337	CbGeAlD
Dasatinib—EPHA2—endometrium—vaginal cancer	0.00263	0.00337	CbGeAlD
Dasatinib—RIPK2—female reproductive system—vaginal cancer	0.00263	0.00337	CbGeAlD
Dasatinib—FYN—endometrium—vaginal cancer	0.00262	0.00337	CbGeAlD
Dasatinib—YES1—uterine cervix—vaginal cancer	0.00262	0.00336	CbGeAlD
Dasatinib—MAP3K3—urethra—vaginal cancer	0.0026	0.00334	CbGeAlD
Dasatinib—MAP4K5—urethra—vaginal cancer	0.0026	0.00334	CbGeAlD
Dasatinib—MAPK14—uterus—vaginal cancer	0.0026	0.00334	CbGeAlD
Dasatinib—LCK—uterus—vaginal cancer	0.00259	0.00333	CbGeAlD
Dasatinib—STK35—female gonad—vaginal cancer	0.00259	0.00332	CbGeAlD
Dasatinib—EPHB4—mammalian vulva—vaginal cancer	0.00259	0.00332	CbGeAlD
Dasatinib—STK35—vagina—vaginal cancer	0.00258	0.0033	CbGeAlD
Dasatinib—CSK—female gonad—vaginal cancer	0.00257	0.0033	CbGeAlD
Dasatinib—JAK2—mammalian vulva—vaginal cancer	0.00257	0.0033	CbGeAlD
Dasatinib—SIK1—female reproductive system—vaginal cancer	0.00256	0.00329	CbGeAlD
Dasatinib—MAP4K5—endometrium—vaginal cancer	0.00256	0.00329	CbGeAlD
Dasatinib—MAP3K3—endometrium—vaginal cancer	0.00256	0.00329	CbGeAlD
Dasatinib—CSK—vagina—vaginal cancer	0.00256	0.00328	CbGeAlD
Dasatinib—EPHA2—mammalian vulva—vaginal cancer	0.00254	0.00326	CbGeAlD
Dasatinib—HCK—female gonad—vaginal cancer	0.00254	0.00326	CbGeAlD
Dasatinib—SRC—epithelium—vaginal cancer	0.00254	0.00326	CbGeAlD
Dasatinib—EPHA4—female reproductive system—vaginal cancer	0.00254	0.00326	CbGeAlD
Dasatinib—FYN—mammalian vulva—vaginal cancer	0.00254	0.00326	CbGeAlD
Dasatinib—HCK—vagina—vaginal cancer	0.00253	0.00324	CbGeAlD
Dasatinib—ABL2—female gonad—vaginal cancer	0.00253	0.00324	CbGeAlD
Dasatinib—SRC—uterine cervix—vaginal cancer	0.00252	0.00323	CbGeAlD
Dasatinib—ERBB3—female reproductive system—vaginal cancer	0.00251	0.00322	CbGeAlD
Dasatinib—ABL2—vagina—vaginal cancer	0.00251	0.00322	CbGeAlD
Dasatinib—MAPK14—Metabolism of mRNA—EIF4A3—vaginal cancer	0.00249	0.0113	CbGpPWpGaD
Dasatinib—MAP3K2—female reproductive system—vaginal cancer	0.00249	0.00319	CbGeAlD
Dasatinib—EPHB6—urethra—vaginal cancer	0.00249	0.00319	CbGeAlD
Dasatinib—MAP4K5—mammalian vulva—vaginal cancer	0.00248	0.00318	CbGeAlD
Dasatinib—MAP3K3—mammalian vulva—vaginal cancer	0.00248	0.00318	CbGeAlD
Dasatinib—EPHB4—uterus—vaginal cancer	0.00247	0.00317	CbGeAlD
Dasatinib—EPHB6—endometrium—vaginal cancer	0.00245	0.00314	CbGeAlD
Dasatinib—FYN—uterus—vaginal cancer	0.00242	0.0031	CbGeAlD
Dasatinib—YES1—urethra—vaginal cancer	0.00241	0.00309	CbGeAlD
Dasatinib—RIPK2—female gonad—vaginal cancer	0.00239	0.00307	CbGeAlD
Dasatinib—RIPK2—vagina—vaginal cancer	0.00237	0.00305	CbGeAlD
Dasatinib—EPHB6—mammalian vulva—vaginal cancer	0.00237	0.00304	CbGeAlD
Dasatinib—YES1—endometrium—vaginal cancer	0.00237	0.00304	CbGeAlD
Dasatinib—MAP4K5—uterus—vaginal cancer	0.00236	0.00303	CbGeAlD
Dasatinib—MAPK14—female reproductive system—vaginal cancer	0.00234	0.003	CbGeAlD
Dasatinib—SIK1—female gonad—vaginal cancer	0.00233	0.00299	CbGeAlD
Dasatinib—FGR—female reproductive system—vaginal cancer	0.00233	0.00299	CbGeAlD
Dasatinib—MAP2K5—uterine cervix—vaginal cancer	0.00232	0.00297	CbGeAlD
Dasatinib—EPHA4—female gonad—vaginal cancer	0.00231	0.00296	CbGeAlD
Dasatinib—EPHA4—vagina—vaginal cancer	0.0023	0.00295	CbGeAlD
Dasatinib—YES1—mammalian vulva—vaginal cancer	0.00229	0.00294	CbGeAlD
Dasatinib—ERBB3—female gonad—vaginal cancer	0.00229	0.00293	CbGeAlD
Dasatinib—MAP3K2—female gonad—vaginal cancer	0.00226	0.00291	CbGeAlD
Dasatinib—CSF1R—uterine cervix—vaginal cancer	0.00226	0.0029	CbGeAlD
Dasatinib—EPHB4—female reproductive system—vaginal cancer	0.00222	0.00285	CbGeAlD
Dasatinib—JAK2—female reproductive system—vaginal cancer	0.0022	0.00283	CbGeAlD
Dasatinib—YES1—uterus—vaginal cancer	0.00218	0.0028	CbGeAlD
Dasatinib—EPHA2—female reproductive system—vaginal cancer	0.00218	0.00279	CbGeAlD
Dasatinib—FYN—female reproductive system—vaginal cancer	0.00217	0.00279	CbGeAlD
Dasatinib—LYN—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00216	0.00979	CbGpPWpGaD
Dasatinib—PDGFRA—uterus—vaginal cancer	0.00214	0.00275	CbGeAlD
Dasatinib—MAPK14—Metabolism of RNA—EIF4A3—vaginal cancer	0.00213	0.00967	CbGpPWpGaD
Dasatinib—MAPK14—female gonad—vaginal cancer	0.00213	0.00273	CbGeAlD
Dasatinib—MAP2K5—urethra—vaginal cancer	0.00213	0.00273	CbGeAlD
Dasatinib—FYN—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00213	0.00964	CbGpPWpGaD
Dasatinib—MAP4K5—female reproductive system—vaginal cancer	0.00212	0.00272	CbGeAlD
Dasatinib—MAP3K3—female reproductive system—vaginal cancer	0.00212	0.00272	CbGeAlD
Dasatinib—FGR—female gonad—vaginal cancer	0.00212	0.00272	CbGeAlD
Dasatinib—LCK—female gonad—vaginal cancer	0.00212	0.00272	CbGeAlD
Dasatinib—MAPK14—vagina—vaginal cancer	0.00212	0.00272	CbGeAlD
Dasatinib—LCK—vagina—vaginal cancer	0.00211	0.0027	CbGeAlD
Dasatinib—FGR—vagina—vaginal cancer	0.00211	0.0027	CbGeAlD
Dasatinib—MAP2K5—endometrium—vaginal cancer	0.00209	0.00269	CbGeAlD
Dasatinib—JAK2—IL27-mediated signaling events—IL2—vaginal cancer	0.00209	0.00948	CbGpPWpGaD
Dasatinib—CSF1R—urethra—vaginal cancer	0.00208	0.00267	CbGeAlD
Dasatinib—STAT5B—Glucocorticoid receptor regulatory network—IL2—vaginal cancer	0.00207	0.00939	CbGpPWpGaD
Dasatinib—KIT—epithelium—vaginal cancer	0.00207	0.00266	CbGeAlD
Dasatinib—KIT—uterine cervix—vaginal cancer	0.00205	0.00263	CbGeAlD
Dasatinib—CSF1R—endometrium—vaginal cancer	0.00204	0.00262	CbGeAlD
Dasatinib—FMO3—vagina—vaginal cancer	0.00204	0.00261	CbGeAlD
Dasatinib—MAP2K5—mammalian vulva—vaginal cancer	0.00203	0.0026	CbGeAlD
Dasatinib—PDGFRB—epithelium—vaginal cancer	0.00202	0.00259	CbGeAlD
Dasatinib—JAK2—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00202	0.00916	CbGpPWpGaD
Dasatinib—EPHB4—female gonad—vaginal cancer	0.00202	0.00259	CbGeAlD
Dasatinib—FYN—T-Cell Receptor and Co-stimulatory Signaling—IL2—vaginal cancer	0.00202	0.00914	CbGpPWpGaD
Dasatinib—EPHB4—vagina—vaginal cancer	0.00201	0.00257	CbGeAlD
Dasatinib—PDGFRB—uterine cervix—vaginal cancer	0.002	0.00257	CbGeAlD
Dasatinib—JAK2—female gonad—vaginal cancer	0.002	0.00257	CbGeAlD
Dasatinib—JAK2—vagina—vaginal cancer	0.00199	0.00256	CbGeAlD
Dasatinib—RIPK2—IL12-mediated signaling events—IL2—vaginal cancer	0.00198	0.009	CbGpPWpGaD
Dasatinib—EPHA2—female gonad—vaginal cancer	0.00198	0.00254	CbGeAlD
Dasatinib—CSF1R—mammalian vulva—vaginal cancer	0.00198	0.00254	CbGeAlD
Dasatinib—FYN—female gonad—vaginal cancer	0.00198	0.00254	CbGeAlD
Dasatinib—JAK2—Interleukin receptor SHC signaling—IL2—vaginal cancer	0.00197	0.00894	CbGpPWpGaD
Dasatinib—EPHA2—vagina—vaginal cancer	0.00197	0.00253	CbGeAlD
Dasatinib—YES1—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00197	0.00892	CbGpPWpGaD
Dasatinib—FYN—vagina—vaginal cancer	0.00197	0.00252	CbGeAlD
Dasatinib—YES1—female reproductive system—vaginal cancer	0.00196	0.00252	CbGeAlD
Dasatinib—MAP4K5—female gonad—vaginal cancer	0.00193	0.00248	CbGeAlD
Dasatinib—MAP3K3—female gonad—vaginal cancer	0.00193	0.00248	CbGeAlD
Dasatinib—PDGFRA—female reproductive system—vaginal cancer	0.00192	0.00247	CbGeAlD
Dasatinib—MAP4K5—vagina—vaginal cancer	0.00192	0.00246	CbGeAlD
Dasatinib—MAP3K3—vagina—vaginal cancer	0.00192	0.00246	CbGeAlD
Dasatinib—SRC—female reproductive system—vaginal cancer	0.00189	0.00242	CbGeAlD
Dasatinib—KIT—urethra—vaginal cancer	0.00189	0.00242	CbGeAlD
Dasatinib—CSF1R—uterus—vaginal cancer	0.00188	0.00242	CbGeAlD
Dasatinib—STAT5B—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00187	0.0085	CbGpPWpGaD
Dasatinib—KIT—endometrium—vaginal cancer	0.00186	0.00238	CbGeAlD
Dasatinib—EPHB6—female gonad—vaginal cancer	0.00185	0.00237	CbGeAlD
Dasatinib—PDGFRB—urethra—vaginal cancer	0.00184	0.00236	CbGeAlD
Dasatinib—EPHB6—vagina—vaginal cancer	0.00184	0.00235	CbGeAlD
Dasatinib—PDGFRB—endometrium—vaginal cancer	0.00181	0.00233	CbGeAlD
Dasatinib—KIT—mammalian vulva—vaginal cancer	0.0018	0.0023	CbGeAlD
Dasatinib—EPHA4—Spinal Cord Injury—IL2—vaginal cancer	0.00179	0.00813	CbGpPWpGaD
Dasatinib—ABL1—uterine cervix—vaginal cancer	0.00179	0.00229	CbGeAlD
Dasatinib—YES1—female gonad—vaginal cancer	0.00178	0.00229	CbGeAlD
Dasatinib—YES1—vagina—vaginal cancer	0.00177	0.00228	CbGeAlD
Dasatinib—LCK—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00177	0.00802	CbGpPWpGaD
Dasatinib—PDGFRB—mammalian vulva—vaginal cancer	0.00175	0.00225	CbGeAlD
Dasatinib—PDGFRA—female gonad—vaginal cancer	0.00175	0.00225	CbGeAlD
Dasatinib—PDGFRA—vagina—vaginal cancer	0.00174	0.00223	CbGeAlD
Dasatinib—MAP2K5—female reproductive system—vaginal cancer	0.00174	0.00223	CbGeAlD
Dasatinib—TXK—Innate Immune System—IFNA1—vaginal cancer	0.00173	0.00783	CbGpPWpGaD
Dasatinib—MAPK14—Toll-like Receptor Signaling Pathway—IFNA1—vaginal cancer	0.00172	0.00778	CbGpPWpGaD
Dasatinib—SRC—female gonad—vaginal cancer	0.00172	0.0022	CbGeAlD
Dasatinib—KIT—uterus—vaginal cancer	0.00171	0.00219	CbGeAlD
Dasatinib—CSF1R—female reproductive system—vaginal cancer	0.00169	0.00217	CbGeAlD
Dasatinib—CSK—Immune System—EIF4A3—vaginal cancer	0.00169	0.00766	CbGpPWpGaD
Dasatinib—LCK—T-Cell Receptor and Co-stimulatory Signaling—IL2—vaginal cancer	0.00168	0.00761	CbGpPWpGaD
Dasatinib—PDGFRB—uterus—vaginal cancer	0.00167	0.00214	CbGeAlD
Dasatinib—MAP3K3—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00166	0.00754	CbGpPWpGaD
Dasatinib—STAT5B—Signaling by Interleukins—IL2—vaginal cancer	0.00166	0.00753	CbGpPWpGaD
Dasatinib—ABL1—urethra—vaginal cancer	0.00164	0.00211	CbGeAlD
Dasatinib—STAT5B—Immune System—EIF4A3—vaginal cancer	0.00164	0.00742	CbGpPWpGaD
Dasatinib—LCK—Inflammatory Response Pathway—IL2—vaginal cancer	0.00163	0.00741	CbGpPWpGaD
Dasatinib—LCK—IL2 signaling events mediated by STAT5—IL2—vaginal cancer	0.00163	0.00741	CbGpPWpGaD
Dasatinib—ABL1—endometrium—vaginal cancer	0.00162	0.00207	CbGeAlD
Dasatinib—LYN—IL-5 Signaling Pathway—IL2—vaginal cancer	0.00158	0.00718	CbGpPWpGaD
Dasatinib—MAP2K5—female gonad—vaginal cancer	0.00158	0.00203	CbGeAlD
Dasatinib—JAK2—IL23-mediated signaling events—IL2—vaginal cancer	0.00158	0.00715	CbGpPWpGaD
Dasatinib—MAP2K5—vagina—vaginal cancer	0.00157	0.00201	CbGeAlD
Dasatinib—ABL1—mammalian vulva—vaginal cancer	0.00156	0.00201	CbGeAlD
Dasatinib—CSF1R—female gonad—vaginal cancer	0.00154	0.00198	CbGeAlD
Dasatinib—KIT—female reproductive system—vaginal cancer	0.00154	0.00197	CbGeAlD
Dasatinib—CSF1R—vagina—vaginal cancer	0.00153	0.00197	CbGeAlD
Dasatinib—PDGFRB—female reproductive system—vaginal cancer	0.0015	0.00193	CbGeAlD
Dasatinib—FYN—IL-2 Signaling Pathway—IL2—vaginal cancer	0.0015	0.0068	CbGpPWpGaD
Dasatinib—ABL1—uterus—vaginal cancer	0.00149	0.00191	CbGeAlD
Dasatinib—HCK—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00149	0.00673	CbGpPWpGaD
Dasatinib—JAK2—IL-5 Signaling Pathway—IL2—vaginal cancer	0.00148	0.00672	CbGpPWpGaD
Dasatinib—MAP3K3—Signaling by Interleukins—IL2—vaginal cancer	0.00147	0.00669	CbGpPWpGaD
Dasatinib—LYN—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00147	0.00665	CbGpPWpGaD
Dasatinib—MAP3K3—Immune System—EIF4A3—vaginal cancer	0.00145	0.00659	CbGpPWpGaD
Dasatinib—FYN—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00144	0.00655	CbGpPWpGaD
Dasatinib—ABL1—Factors involved in megakaryocyte development and platelet production—IFNA1—vaginal cancer	0.00143	0.00649	CbGpPWpGaD
Dasatinib—BTK—Immune System—EIF4A3—vaginal cancer	0.00141	0.00641	CbGpPWpGaD
Dasatinib—RIPK2—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.0014	0.00634	CbGpPWpGaD
Dasatinib—KIT—female gonad—vaginal cancer	0.0014	0.0018	CbGeAlD
Dasatinib—KIT—vagina—vaginal cancer	0.00139	0.00178	CbGeAlD
Dasatinib—LCK—IL2 signaling events mediated by PI3K—IL2—vaginal cancer	0.00138	0.00626	CbGpPWpGaD
Dasatinib—JAK2—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00137	0.00623	CbGpPWpGaD
Dasatinib—PDGFRB—female gonad—vaginal cancer	0.00137	0.00175	CbGeAlD
Dasatinib—PDGFRB—vagina—vaginal cancer	0.00136	0.00174	CbGeAlD
Dasatinib—JAK2—Factors involved in megakaryocyte development and platelet production—IFNA1—vaginal cancer	0.00135	0.0061	CbGpPWpGaD
Dasatinib—LYN—GPVI-mediated activation cascade—IL2—vaginal cancer	0.00135	0.0061	CbGpPWpGaD
Dasatinib—MAPK14—Regulation of toll-like receptor signaling pathway—IFNA1—vaginal cancer	0.00134	0.00608	CbGpPWpGaD
Dasatinib—ABL1—female reproductive system—vaginal cancer	0.00134	0.00172	CbGeAlD
Dasatinib—FYN—GPVI-mediated activation cascade—IL2—vaginal cancer	0.00133	0.00601	CbGpPWpGaD
Dasatinib—HCK—Signaling by Interleukins—IL2—vaginal cancer	0.00132	0.00597	CbGpPWpGaD
Dasatinib—JAK2—Interleukin-2 signaling—IL2—vaginal cancer	0.0013	0.00591	CbGpPWpGaD
Dasatinib—HCK—Immune System—EIF4A3—vaginal cancer	0.0013	0.00588	CbGpPWpGaD
Dasatinib—JAK2—G beta:gamma signalling through PI3Kgamma—IL2—vaginal cancer	0.00128	0.00581	CbGpPWpGaD
Dasatinib—CYP1B1—uterus—vaginal cancer	0.00126	0.00162	CbGeAlD
Dasatinib—JAK2—GPVI-mediated activation cascade—IL2—vaginal cancer	0.00126	0.00571	CbGpPWpGaD
Dasatinib—LCK—IL-2 Signaling Pathway—IL2—vaginal cancer	0.00125	0.00566	CbGpPWpGaD
Dasatinib—RIPK2—Signaling by Interleukins—IL2—vaginal cancer	0.00124	0.00562	CbGpPWpGaD
Dasatinib—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL2—vaginal cancer	0.00124	0.0056	CbGpPWpGaD
Dasatinib—FYN—IL2-mediated signaling events—IL2—vaginal cancer	0.00123	0.00556	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—EIF4A3—vaginal cancer	0.00122	0.00554	CbGpPWpGaD
Dasatinib—JAK2—G-protein beta:gamma signalling—IL2—vaginal cancer	0.00122	0.00553	CbGpPWpGaD
Dasatinib—ABL1—female gonad—vaginal cancer	0.00122	0.00156	CbGeAlD
Dasatinib—ABL1—vagina—vaginal cancer	0.00121	0.00155	CbGeAlD
Dasatinib—CSK—Hemostasis—IFNA1—vaginal cancer	0.00121	0.00546	CbGpPWpGaD
Dasatinib—PDGFRB—SHP2 signaling—IL2—vaginal cancer	0.0012	0.00545	CbGpPWpGaD
Dasatinib—SRMS—Immune System—IFNA1—vaginal cancer	0.00118	0.00537	CbGpPWpGaD
Dasatinib—MAPK14—IL2-mediated signaling events—IL2—vaginal cancer	0.00118	0.00535	CbGpPWpGaD
Dasatinib—BLK—Immune System—EIF4A3—vaginal cancer	0.00118	0.00533	CbGpPWpGaD
Dasatinib—FGR—Immune System—EIF4A3—vaginal cancer	0.00117	0.00531	CbGpPWpGaD
Dasatinib—LCK—Interleukin-2 signaling—IL2—vaginal cancer	0.00114	0.00517	CbGpPWpGaD
Dasatinib—CYP1B1—female reproductive system—vaginal cancer	0.00113	0.00145	CbGeAlD
Dasatinib—JAK2—Interferon Signaling—IFNA1—vaginal cancer	0.00113	0.00513	CbGpPWpGaD
Dasatinib—ABCG2—uterine cervix—vaginal cancer	0.00113	0.00145	CbGeAlD
Dasatinib—LCK—GPVI-mediated activation cascade—IL2—vaginal cancer	0.0011	0.005	CbGpPWpGaD
Dasatinib—JAK2—SHP2 signaling—IL2—vaginal cancer	0.0011	0.00499	CbGpPWpGaD
Dasatinib—MAPK14—IL12-mediated signaling events—IL2—vaginal cancer	0.00109	0.00492	CbGpPWpGaD
Dasatinib—YES1—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00108	0.00491	CbGpPWpGaD
Dasatinib—CYP1A1—epithelium—vaginal cancer	0.00108	0.00138	CbGeAlD
Dasatinib—ERBB3—Immune System—EIF4A3—vaginal cancer	0.00108	0.00489	CbGpPWpGaD
Dasatinib—JAK2—IL12-mediated signaling events—IL2—vaginal cancer	0.00107	0.00486	CbGpPWpGaD
Dasatinib—CYP1A1—uterine cervix—vaginal cancer	0.00107	0.00137	CbGeAlD
Dasatinib—CYP3A5—uterine cervix—vaginal cancer	0.00105	0.00134	CbGeAlD
Dasatinib—PDGFRA—Allograft Rejection—IL2—vaginal cancer	0.00104	0.00472	CbGpPWpGaD
Dasatinib—ABCG2—urethra—vaginal cancer	0.00104	0.00133	CbGeAlD
Dasatinib—CYP1B1—female gonad—vaginal cancer	0.00103	0.00132	CbGeAlD
Dasatinib—ABL1—Regulation of Telomerase—IL2—vaginal cancer	0.00103	0.00467	CbGpPWpGaD
Dasatinib—SRC—Aryl Hydrocarbon Receptor Pathway—IL2—vaginal cancer	0.00103	0.00466	CbGpPWpGaD
Dasatinib—LCK—IL2-mediated signaling events—IL2—vaginal cancer	0.00102	0.00463	CbGpPWpGaD
Dasatinib—ABCG2—endometrium—vaginal cancer	0.00102	0.00131	CbGeAlD
Dasatinib—TXK—Immune System—IFNA1—vaginal cancer	0.00101	0.00456	CbGpPWpGaD
Dasatinib—ABCG2—mammalian vulva—vaginal cancer	0.000986	0.00126	CbGeAlD
Dasatinib—CYP1A1—urethra—vaginal cancer	0.000983	0.00126	CbGeAlD
Dasatinib—CSK—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000967	0.00438	CbGpPWpGaD
Dasatinib—LCK—SHP2 signaling—IL2—vaginal cancer	0.000964	0.00437	CbGpPWpGaD
Dasatinib—YES1—Signaling by Interleukins—IL2—vaginal cancer	0.00096	0.00435	CbGpPWpGaD
Dasatinib—YES1—Immune System—EIF4A3—vaginal cancer	0.000946	0.00429	CbGpPWpGaD
Dasatinib—ABCG2—uterus—vaginal cancer	0.000939	0.0012	CbGeAlD
Dasatinib—LCK—IL12-mediated signaling events—IL2—vaginal cancer	0.000939	0.00425	CbGpPWpGaD
Dasatinib—CYP1A1—mammalian vulva—vaginal cancer	0.000936	0.0012	CbGeAlD
Dasatinib—BTK—Innate Immune System—IFNA1—vaginal cancer	0.000908	0.00412	CbGpPWpGaD
Dasatinib—CYP1A1—uterus—vaginal cancer	0.000892	0.00114	CbGeAlD
Dasatinib—MAPK14—Glucocorticoid receptor regulatory network—IL2—vaginal cancer	0.000845	0.00383	CbGpPWpGaD
Dasatinib—KIT—Immune System—EIF4A3—vaginal cancer	0.000845	0.00383	CbGpPWpGaD
Dasatinib—FGR—Hemostasis—IFNA1—vaginal cancer	0.000836	0.00379	CbGpPWpGaD
Dasatinib—HCK—Innate Immune System—IFNA1—vaginal cancer	0.000833	0.00378	CbGpPWpGaD
Dasatinib—LYN—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000807	0.00366	CbGpPWpGaD
Dasatinib—CYP1A1—female reproductive system—vaginal cancer	0.000801	0.00103	CbGeAlD
Dasatinib—PDGFRA—Immune System—EIF4A3—vaginal cancer	0.0008	0.00363	CbGpPWpGaD
Dasatinib—FYN—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000795	0.0036	CbGpPWpGaD
Dasatinib—RIPK2—Innate Immune System—IFNA1—vaginal cancer	0.000785	0.00356	CbGpPWpGaD
Dasatinib—STAT5B—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000775	0.00351	CbGpPWpGaD
Dasatinib—MAPK14—Corticotropin-releasing hormone—IL2—vaginal cancer	0.000771	0.0035	CbGpPWpGaD
Dasatinib—ABCG2—female gonad—vaginal cancer	0.000768	0.000986	CbGeAlD
Dasatinib—ABCG2—vagina—vaginal cancer	0.000763	0.00098	CbGeAlD
Dasatinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—vaginal cancer	0.000761	0.00345	CbGpPWpGaD
Dasatinib—JAK2—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000756	0.00343	CbGpPWpGaD
Dasatinib—FGR—Innate Immune System—IFNA1—vaginal cancer	0.000752	0.00341	CbGpPWpGaD
Dasatinib—CYP1A1—female gonad—vaginal cancer	0.000729	0.000936	CbGeAlD
Dasatinib—CYP1A1—vagina—vaginal cancer	0.000725	0.00093	CbGeAlD
Dasatinib—PDGFRB—Immune System—EIF4A3—vaginal cancer	0.00072	0.00327	CbGpPWpGaD
Dasatinib—LYN—Signaling by Interleukins—IL2—vaginal cancer	0.000716	0.00324	CbGpPWpGaD
Dasatinib—CYP3A5—female gonad—vaginal cancer	0.000713	0.000915	CbGeAlD
Dasatinib—CYP3A5—vagina—vaginal cancer	0.000709	0.000909	CbGeAlD
Dasatinib—LYN—Immune System—EIF4A3—vaginal cancer	0.000705	0.0032	CbGpPWpGaD
Dasatinib—FYN—Signaling by Interleukins—IL2—vaginal cancer	0.000704	0.00319	CbGpPWpGaD
Dasatinib—ABL1—Immune System—EIF4A3—vaginal cancer	0.000702	0.00318	CbGpPWpGaD
Dasatinib—FYN—Immune System—EIF4A3—vaginal cancer	0.000694	0.00315	CbGpPWpGaD
Dasatinib—ERBB3—Innate Immune System—IFNA1—vaginal cancer	0.000692	0.00314	CbGpPWpGaD
Dasatinib—MAP3K3—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000688	0.00312	CbGpPWpGaD
Dasatinib—YES1—Hemostasis—IFNA1—vaginal cancer	0.000675	0.00306	CbGpPWpGaD
Dasatinib—JAK2—Signaling by Interleukins—IL2—vaginal cancer	0.00067	0.00304	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—EIF4A3—vaginal cancer	0.000669	0.00303	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—EIF4A3—vaginal cancer	0.000665	0.00301	CbGpPWpGaD
Dasatinib—LCK—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000662	0.003	CbGpPWpGaD
Dasatinib—JAK2—Immune System—EIF4A3—vaginal cancer	0.00066	0.00299	CbGpPWpGaD
Dasatinib—CSK—Immune System—IFNA1—vaginal cancer	0.000632	0.00287	CbGpPWpGaD
Dasatinib—HCK—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000614	0.00278	CbGpPWpGaD
Dasatinib—STAT5B—Immune System—IFNA1—vaginal cancer	0.000612	0.00278	CbGpPWpGaD
Dasatinib—YES1—Innate Immune System—IFNA1—vaginal cancer	0.000607	0.00275	CbGpPWpGaD
Dasatinib—CYP3A4—female reproductive system—vaginal cancer	0.000588	0.000755	CbGeAlD
Dasatinib—LCK—Signaling by Interleukins—IL2—vaginal cancer	0.000586	0.00266	CbGpPWpGaD
Dasatinib—RIPK2—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000579	0.00262	CbGpPWpGaD
Dasatinib—LCK—Immune System—EIF4A3—vaginal cancer	0.000578	0.00262	CbGpPWpGaD
Dasatinib—ABCB1—epithelium—vaginal cancer	0.00056	0.000719	CbGeAlD
Dasatinib—ABCB1—uterine cervix—vaginal cancer	0.000556	0.000713	CbGeAlD
Dasatinib—MAP3K3—Immune System—IFNA1—vaginal cancer	0.000544	0.00246	CbGpPWpGaD
Dasatinib—KIT—Innate Immune System—IFNA1—vaginal cancer	0.000542	0.00246	CbGpPWpGaD
Dasatinib—BTK—Immune System—IFNA1—vaginal cancer	0.000529	0.0024	CbGpPWpGaD
Dasatinib—PDGFRA—Innate Immune System—IFNA1—vaginal cancer	0.000513	0.00233	CbGpPWpGaD
Dasatinib—SRC—Immune System—EIF4A3—vaginal cancer	0.000512	0.00232	CbGpPWpGaD
Dasatinib—ABCB1—urethra—vaginal cancer	0.000511	0.000655	CbGeAlD
Dasatinib—LYN—Hemostasis—IFNA1—vaginal cancer	0.000503	0.00228	CbGpPWpGaD
Dasatinib—ABCB1—endometrium—vaginal cancer	0.000503	0.000645	CbGeAlD
Dasatinib—ABL1—Hemostasis—IFNA1—vaginal cancer	0.000501	0.00227	CbGpPWpGaD
Dasatinib—CSK—Hemostasis—IL2—vaginal cancer	0.000499	0.00226	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—IFNA1—vaginal cancer	0.000495	0.00224	CbGpPWpGaD
Dasatinib—SRMS—Immune System—IL2—vaginal cancer	0.00049	0.00222	CbGpPWpGaD
Dasatinib—ABCB1—mammalian vulva—vaginal cancer	0.000486	0.000624	CbGeAlD
Dasatinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—vaginal cancer	0.000485	0.0022	CbGpPWpGaD
Dasatinib—HCK—Immune System—IFNA1—vaginal cancer	0.000485	0.0022	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—IFNA1—vaginal cancer	0.000477	0.00216	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—IFNA1—vaginal cancer	0.000471	0.00213	CbGpPWpGaD
Dasatinib—ABCB1—uterus—vaginal cancer	0.000463	0.000594	CbGeAlD
Dasatinib—PDGFRB—Innate Immune System—IFNA1—vaginal cancer	0.000462	0.0021	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—IFNA1—vaginal cancer	0.000457	0.00207	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—IFNA1—vaginal cancer	0.000453	0.00205	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—IFNA1—vaginal cancer	0.000451	0.00204	CbGpPWpGaD
Dasatinib—YES1—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000448	0.00203	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—IFNA1—vaginal cancer	0.000446	0.00202	CbGpPWpGaD
Dasatinib—BLK—Immune System—IFNA1—vaginal cancer	0.00044	0.00199	CbGpPWpGaD
Dasatinib—FGR—Immune System—IFNA1—vaginal cancer	0.000438	0.00199	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—IFNA1—vaginal cancer	0.000429	0.00195	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—IFNA1—vaginal cancer	0.000424	0.00192	CbGpPWpGaD
Dasatinib—TXK—Immune System—IL2—vaginal cancer	0.000416	0.00189	CbGpPWpGaD
Dasatinib—ABCB1—female reproductive system—vaginal cancer	0.000416	0.000534	CbGeAlD
Dasatinib—LCK—Hemostasis—IFNA1—vaginal cancer	0.000412	0.00187	CbGpPWpGaD
Dasatinib—LYN—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000404	0.00183	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—IFNA1—vaginal cancer	0.000403	0.00183	CbGpPWpGaD
Dasatinib—FYN—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000397	0.0018	CbGpPWpGaD
Dasatinib—ABCB1—Allograft Rejection—IL2—vaginal cancer	0.000394	0.00179	CbGpPWpGaD
Dasatinib—MAPK14—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000383	0.00173	CbGpPWpGaD
Dasatinib—ABCB1—female gonad—vaginal cancer	0.000379	0.000486	CbGeAlD
Dasatinib—JAK2—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000378	0.00171	CbGpPWpGaD
Dasatinib—ABCB1—vagina—vaginal cancer	0.000376	0.000483	CbGeAlD
Dasatinib—LCK—Innate Immune System—IFNA1—vaginal cancer	0.000371	0.00168	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—IFNA1—vaginal cancer	0.000365	0.00165	CbGpPWpGaD
Dasatinib—YES1—Immune System—IFNA1—vaginal cancer	0.000354	0.0016	CbGpPWpGaD
Dasatinib—FGR—Hemostasis—IL2—vaginal cancer	0.000346	0.00157	CbGpPWpGaD
Dasatinib—LYN—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000334	0.00151	CbGpPWpGaD
Dasatinib—LCK—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000331	0.0015	CbGpPWpGaD
Dasatinib—FYN—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000329	0.00149	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—IFNA1—vaginal cancer	0.000329	0.00149	CbGpPWpGaD
Dasatinib—KIT—Immune System—IFNA1—vaginal cancer	0.000316	0.00143	CbGpPWpGaD
Dasatinib—JAK2—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000312	0.00142	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IFNA1—vaginal cancer	0.000299	0.00136	CbGpPWpGaD
Dasatinib—SRC—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000293	0.00133	CbGpPWpGaD
Dasatinib—YES1—Hemostasis—IL2—vaginal cancer	0.000279	0.00126	CbGpPWpGaD
Dasatinib—LCK—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000274	0.00124	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IFNA1—vaginal cancer	0.000269	0.00122	CbGpPWpGaD
Dasatinib—LYN—Immune System—IFNA1—vaginal cancer	0.000264	0.0012	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IFNA1—vaginal cancer	0.000263	0.00119	CbGpPWpGaD
Dasatinib—CSK—Immune System—IL2—vaginal cancer	0.000261	0.00118	CbGpPWpGaD
Dasatinib—FYN—Immune System—IFNA1—vaginal cancer	0.00026	0.00118	CbGpPWpGaD
Dasatinib—STAT5B—Immune System—IL2—vaginal cancer	0.000253	0.00115	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IFNA1—vaginal cancer	0.00025	0.00113	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IFNA1—vaginal cancer	0.000247	0.00112	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—IL2—vaginal cancer	0.00024	0.00109	CbGpPWpGaD
Dasatinib—MAP3K3—Immune System—IL2—vaginal cancer	0.000225	0.00102	CbGpPWpGaD
Dasatinib—BTK—Immune System—IL2—vaginal cancer	0.000219	0.000991	CbGpPWpGaD
Dasatinib—LCK—Immune System—IFNA1—vaginal cancer	0.000216	0.00098	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—IL2—vaginal cancer	0.000208	0.000943	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—IL2—vaginal cancer	0.000207	0.000938	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—IL2—vaginal cancer	0.000205	0.000928	CbGpPWpGaD
Dasatinib—HCK—Immune System—IL2—vaginal cancer	0.000201	0.00091	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—IL2—vaginal cancer	0.000197	0.000894	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—IL2—vaginal cancer	0.000195	0.000882	CbGpPWpGaD
Dasatinib—SRC—Immune System—IFNA1—vaginal cancer	0.000191	0.000867	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—IL2—vaginal cancer	0.000189	0.000857	CbGpPWpGaD
Dasatinib—BLK—Immune System—IL2—vaginal cancer	0.000182	0.000824	CbGpPWpGaD
Dasatinib—FGR—Immune System—IL2—vaginal cancer	0.000181	0.000821	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—IL2—vaginal cancer	0.00017	0.000773	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—IL2—vaginal cancer	0.000169	0.000766	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—IL2—vaginal cancer	0.000167	0.000755	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—IL2—vaginal cancer	0.000164	0.000742	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—IL2—vaginal cancer	0.000151	0.000684	CbGpPWpGaD
Dasatinib—YES1—Immune System—IL2—vaginal cancer	0.000146	0.000663	CbGpPWpGaD
Dasatinib—KIT—Immune System—IL2—vaginal cancer	0.000131	0.000592	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL2—vaginal cancer	0.000124	0.00056	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—IL2—vaginal cancer	0.000123	0.000558	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—IL2—vaginal cancer	0.000122	0.000554	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL2—vaginal cancer	0.000112	0.000507	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL2—vaginal cancer	0.000112	0.000506	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL2—vaginal cancer	0.000111	0.000505	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL2—vaginal cancer	0.000109	0.000494	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL2—vaginal cancer	0.000109	0.000492	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL2—vaginal cancer	0.000108	0.000488	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL2—vaginal cancer	0.000107	0.000487	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL2—vaginal cancer	0.000103	0.000469	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL2—vaginal cancer	0.000102	0.000463	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL2—vaginal cancer	9.46e-05	0.000429	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL2—vaginal cancer	8.94e-05	0.000405	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL2—vaginal cancer	8.45e-05	0.000383	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL2—vaginal cancer	7.99e-05	0.000362	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL2—vaginal cancer	7.91e-05	0.000359	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL2—vaginal cancer	7.2e-05	0.000326	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL2—vaginal cancer	7.05e-05	0.00032	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL2—vaginal cancer	6.94e-05	0.000315	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL2—vaginal cancer	6.68e-05	0.000303	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL2—vaginal cancer	6.6e-05	0.000299	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—vaginal cancer	5.78e-05	0.000262	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—vaginal cancer	5.12e-05	0.000232	CbGpPWpGaD
